Cochrane Review Group
Gynaecological, Neuro-oncology and Orphan Cancer
129 systematic reviews in Gynaecological, Neuro-oncology and Orphan Cancer ask 1,590 questions. 17.7% have no studies to answer them, 25.8% rest on very low certainty evidence and 25.5% reach moderate or high certainty.
Reviews
129
Questions
1,590
current versions
No studies
17.7%
Moderate or high
25.5%
No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 2 studies · 964 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 5 studies · 1968 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 6 studies · 2184 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 3 studies · 1222 participants | Very low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 129
Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis
CochraneSoF table
10 questions
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery
CochraneSoF table
5 questions
Extended‐field radiotherapy for locally advanced cervical cancer
CochraneSoF table
14 questions
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
CochraneSoF table
32 questions
Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers
CochraneSoF table
113 questions
Intraoperative imaging technology to maximise extent of resection for glioma
CochraneSoF table
12 questions
Home parenteral nutrition for people with inoperable malignant bowel obstruction
CochraneSoF table
3 questions
Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer
CochraneSoF table
4 questions
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases
CochraneSoF table
5 questions
Parenteral anticoagulation in ambulatory patients with cancer
CochraneSoF table
7 questions
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia
CochraneSoF table
4 questions
Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies
CochraneSoF table
7 questions
Lymphadenectomy for the management of endometrial cancer
CochraneSoF table
5 questions
Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas
CochraneSoF table
6 questions
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
CochraneSoF table
7 questions
Antibiotics for infection prevention after excision of the cervical transformation zone
CochraneSoF table
7 questions
Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility
CochraneSoF table
9 questions
Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
CochraneSoF table
6 questions
Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease
CochraneSoF table
12 questions
Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction
CochraneSoF table
7 questions
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
CochraneSoF table
10 questions
Adjuvant platinum‐based chemotherapy for early stage cervical cancer
CochraneSoF table
4 questions
Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
CochraneSoF table
3 questions
First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia
CochraneSoF table
5 questions
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer
CochraneSoF table
7 questions